Reata Pharmaceuticals shares are trading lower after the company announced the outcome of the FDA Advisory Committee meeting on bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome. The committee voted ‘No’ on a question regarding effectiveness.